Fred Poordad, MD, on Ethnic Differences in Telaprevir Treatment Effect
Feb 17, 2012 |
In this video Fred Poordad, MD, Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center evaluates the effect of race on the response to treatment and viral resistance profiles with telaprevir combination therapy.
The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem.
But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.